Aripiprazole lauroxil was developed based on Alkermes’ proprietary LinkeRx ® technology and is designed to provide dosing flexibility to address the unique needs of patients with schizophrenia. Once ...

The company’s regulatory submission included results from the pivotal phase III study on the efficacy and safety of aripiprazole lauroxil. The randomized, multicenter, double-blind, placebo-controlled ...

Alkermes announced results from its Phase 3 trial of aripiprazole lauroxil, an investigational drug for the treatment of schizophrenia. Aripiprazole lauroxil is an injectable atypical antipsychotic ...

Alkermes announced positive results from its Phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Aripiprazole lauroxil, which utilizes Alkermes’ proprietary LinkeRx ...

A week doesn’t go by without seeing the horrors of yet another mass shooting. Be it in schools, theatres, or shopping malls, these reports cause all of us to wonder immediately where our loved ones ...

) today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once ...

On Monday, May 7, during a poster session at the 2018 Annual Meeting of the American Psychiatric Association, researchers presented new data on the injectable antipsychotic treatment aripiprazole ...

DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of aripiprazole ...

In a recent press release, Alkermes plc (Nasdaq: ALKS) announced that the U.S. Food and Drug Administration (FDA) has approved ARISTADA INITIO™ (aripiprazole lauroxil) for the initiation of ARISTADA® ...

On October 5, the U.S. Food and Drug Administration approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia. Aristada is administered by a health care ...

NEW YORK CITY -- An investigational 1-day aripiprazole initiation regimen was comparable in efficacy to usual treatment, according to a phase I study presented here. For the treatment of schizophrenia ...

Alkermes ( ALKS) submitted a New Drug Application (NDA) for aripiprazole lauroxil in the U.S. The company is looking to get aripiprazole lauroxil approved for the treatment of schizophrenia. Alkermes ...